The association of markers of cerebral small vessel disease and brain atrophy with incidence and course of depressive symptoms - the maastricht study. Geraets, A. F., Kohler, S., Jansen, J. F., Eussen, S. J., Stehouwer, C. D., Schaper, N. C., Wesselius, A., Verhey, F. R., & Schram, M. T. J Affect Disord, 292:439-447, 2021. Geraets, Anouk Fj Kohler, Sebastian Jansen, Jacobus Fa Eussen, Simone Jpm Stehouwer, Coen DA Schaper, Nicolaas C Wesselius, Anke Verhey, Frans Rj Schram, Miranda T eng Research Support, Non-U.S. Gov't Netherlands J Affect Disord. 2021 Sep 1;292:439-447. doi: 10.1016/j.jad.2021.05.096. Epub 2021 Jun 9.
The association of markers of cerebral small vessel disease and brain atrophy with incidence and course of depressive symptoms - the maastricht study [link]Paper  doi  abstract   bibtex   
BACKGROUND: Cerebral small vessel disease (CSVD) and neurodegeneration may be involved in the development and persistence of late-life depressive symptoms, but longitudinal evidence is scarce. We investigated the longitudinal associations of markers of CSVD and brain atrophy with incident depressive symptoms and the course of depressive symptoms, above and below 60 years of age. METHODS: White matter hyperintensity volumes (WMH), presence of lacunar infarcts and cerebral microbleeds, and white matter, grey matter, and cerebral spinal fluid volumes were assessed at baseline by 3T MRI in The Maastricht Study (mean age 59.5+/-8.5 years, 49.6% women, n=4,347; 16,535 person-years of follow-up). Clinically relevant depressive symptoms (9-item Patient Health Questionnaire>/=10) were assessed at baseline and annually over seven years. We used Cox regression and multinomial logistic regression analyses adjusted for demographic, cardiovascular, and lifestyle risk factors. RESULTS: Above 60 years of age, larger WMH volumes were associated with an increased risk for incident depressive symptoms (HR[95%CI]:1.24[1.04;1.48] per SD) and a persistent course of depressive symptoms (OR:1.44[1.04;2.00] per SD). Total CSVD burden was associated with persistent depressive symptoms irrespective of age (adjusted OR:1.58[1.03;2.43]), while no associations were found for general markers of brain atrophy. LIMITATIONSS: Our findings need replication in other large-scale population-based studies. CONCLUSIONS: Our findings may suggest a temporal association of larger WMH volume with the incidence and persistence of late-life depression in the general population and may provide a potential target for the prevention of chronic late-life depression.
@article{RN295,
   author = {Geraets, A. F. and Kohler, S. and Jansen, J. F. and Eussen, S. J. and Stehouwer, C. D. and Schaper, N. C. and Wesselius, A. and Verhey, F. R. and Schram, M. T.},
   title = {The association of markers of cerebral small vessel disease and brain atrophy with incidence and course of depressive symptoms - the maastricht study},
   journal = {J Affect Disord},
   volume = {292},
   pages = {439-447},
   note = {Geraets, Anouk Fj
Kohler, Sebastian
Jansen, Jacobus Fa
Eussen, Simone Jpm
Stehouwer, Coen DA
Schaper, Nicolaas C
Wesselius, Anke
Verhey, Frans Rj
Schram, Miranda T
eng
Research Support, Non-U.S. Gov't
Netherlands
J Affect Disord. 2021 Sep 1;292:439-447. doi: 10.1016/j.jad.2021.05.096. Epub 2021 Jun 9.},
   abstract = {BACKGROUND: Cerebral small vessel disease (CSVD) and neurodegeneration may be involved in the development and persistence of late-life depressive symptoms, but longitudinal evidence is scarce. We investigated the longitudinal associations of markers of CSVD and brain atrophy with incident depressive symptoms and the course of depressive symptoms, above and below 60 years of age. METHODS: White matter hyperintensity volumes (WMH), presence of lacunar infarcts and cerebral microbleeds, and white matter, grey matter, and cerebral spinal fluid volumes were assessed at baseline by 3T MRI in The Maastricht Study (mean age 59.5+/-8.5 years, 49.6% women, n=4,347; 16,535 person-years of follow-up). Clinically relevant depressive symptoms (9-item Patient Health Questionnaire>/=10) were assessed at baseline and annually over seven years. We used Cox regression and multinomial logistic regression analyses adjusted for demographic, cardiovascular, and lifestyle risk factors. RESULTS: Above 60 years of age, larger WMH volumes were associated with an increased risk for incident depressive symptoms (HR[95%CI]:1.24[1.04;1.48] per SD) and a persistent course of depressive symptoms (OR:1.44[1.04;2.00] per SD). Total CSVD burden was associated with persistent depressive symptoms irrespective of age (adjusted OR:1.58[1.03;2.43]), while no associations were found for general markers of brain atrophy. LIMITATIONSS: Our findings need replication in other large-scale population-based studies. CONCLUSIONS: Our findings may suggest a temporal association of larger WMH volume with the incidence and persistence of late-life depression in the general population and may provide a potential target for the prevention of chronic late-life depression.},
   keywords = {Aged
Atrophy
*Cerebral Small Vessel Diseases/diagnostic imaging/epidemiology
Depression/epidemiology
Female
Humans
Incidence
Magnetic Resonance Imaging
Male
Middle Aged
*White Matter/diagnostic imaging
*Brain atrophy
*Cerebral small vessel disease
*Cohort studies
*Depression
*Depressive symptoms
*Epidemiology},
   ISSN = {1573-2517 (Electronic)
0165-0327 (Linking)},
   DOI = {10.1016/j.jad.2021.05.096},
   url = {https://www.ncbi.nlm.nih.gov/pubmed/34144369},
   year = {2021},
   type = {Journal Article}
}

Downloads: 0